Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling

GUI'E XIE1*, XINPEI YU2,3*, HUICHAO LIANG4, JINGSONG CHEN4, XUEWEI TANG4, SHAOQING WU4 and CAN LIAO5

1KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong 510182; 2Cancer Center; 3Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315; 4Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, P.R. China

Received January 3, 2015; Accepted February 5, 2016

DOI: 10.3892/ol.2016.4335

Abstract. Breast cancer remains a major public health problem worldwide. Chemotherapy serves an important role in the treatment of breast cancer. However, resistance to chemotherapeutic agents, in particular, multi-drug resistance (MDR), is a major cause of treatment failure in cancer. Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. Pristimerin, a quinonemethide triterpenoid compound isolated from Celastraceae and Hippocrateaceae, has been shown to possess antitumor, anti-inflammatory, antioxidant and insecticidal properties. The aim of the present study was to investigate whether pristimerin can override chemoresistance in MCF-7/adriamycin (ADR)-resistant human breast cancer cells. The results demonstrated that pristimerin indeed displayed potent cytocidal effect on multidrug-resistant MCF-7/ADR breast cancer cells, and that these effects occurred through the suppression of Akt signaling, which in turn led to the downregulation of antiapoptotic effectors and increased apoptosis. These findings indicate that use of pristimerin may represent a potentially promising approach for the treatment of ADR-resistant breast cancer.

Introduction

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-associated mortality among females (1,2), accounting for 23% of the total cancer cases and 14% of cancer mortalities (3). Chemotherapy serves an important role in the treatment of breast cancer. However, resistance to chemotherapeutic agents, in particular, multi-drug resistance (MDR), is an major cause of treatment failure in cancer. The MDR mechanisms are complicated, involving increased drug efflux, reduced drug uptake, altered metabolism of drugs, altered expression of drug targets, reduced affinity of drug targets, activation of the detoxification system, enhanced repair of drug-induced defects and blocked apoptosis (4). Hence, identification of novel and effective agents that reverse drug resistance in breast cancer is urgently needed.

Pristimerin is a quinonemethide triterpenoid compound isolated from Celastraceae and Hippocrateaceae and has long been used as anti-inflammatory, antioxidant, antimalarial and insecticidal agents (5). In addition, it has been reported that pristimerin has promising clinical potential as both a therapeutic and chemopreventive agent for various types of cancer such as pancreatic cancer, glioma, leukemia, cervical cancer, prostate cancer and breast cancer (6-11). Pristimerin has been shown to induce cell death via a number of several mechanisms, including proteosome inhibition, caspase activation, inhibition of cell cycle progression, and suppression of anti-apoptotic nuclear factor kappa B (NF-κB) and Akt signaling pathways (6,9). In breast cancer, it has been reported that pristimerin has promising clinical potential as both a therapeutic and chemopreventive agent for various types of cancer such as pancreatic cancer, glioma, leukemia, cervical cancer, prostate cancer and breast cancer (6-11). Pristimerin has been shown to induce cell death via a number of several mechanisms, including proteosome inhibition, caspase activation, inhibition of cell cycle progression, and suppression of anti-apoptotic nuclear factor kappa B (NF-κB) and Akt signaling pathways (6,9). In breast cancer, it has been reported that pristimerin induces apoptotic cell death in MDA-MB-231 breast cancer cells in a caspase-dependent manner (11). In addition, pristimerin has been demonstrated to inhibit the migration and invasion of breast cancer cells (12). However, to the best of our knowledge, the function of pristimerin on chemoresistance in human breast cancer has not yet been investigated.

The present study aims to address whether pristimerin can reverse chemoresistance in human breast cancer cells. The results demonstrated that pristimerin indeed suppressed the proliferation of ADR-resistant MCF-7/ADR breast cancer cells, and that these effects occurred through the suppression of Akt signaling, which in turn led to the downregulation...
of antiapoptotic effectors and increased apoptosis. These findings indicate that pristimerin may have potential in the treatment of ADR-resistant breast cancer.

Materials and methods

Chemicals. Pristimerin and ADR were obtained from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO) to give a stock solution of 1.0 mM and stored at -20˚C in small aliquots.

Cell culture. MCF-7 and MCF-7/ADR human breast cancer cells were purchased from Nanjing KeyGen Biotech. Co. Ltd. (Nanjing, China). The cells were grown in Dulbecco’s modified Eagle medium (Invitrogen™; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA). MCF-7/ADR cells were cultured in the above medium containing 1.0 µM ADR in order to maintain the ADR-resistant phenotype, upon treatment with or without pristimerin.

Cell viability analysis. Cells were seeded in 96-well flat-bottom plates at a density of 1x10⁴ cells per well and cultured in a humidified incubator for 24 h in the absence or presence of the indicated concentrations of pristimerin and 1.0 µM ADR for additional 48 h. Cell viability was measured by using the MTS assay as described previously (13). The concentration of drug that inhibited cell survival by 50% (IC₅₀) was calculated by Bliss’s software (14). The resistance factor (RF) was determined from the ratio of the IC₅₀ for MCF-7/ADR to the IC₅₀ for the sensitive cell line MCF-7. The data are presented as mean ± standard deviation from 3 independent experiments.

Annexin V-FITC (fluorescein isothiocyanate)/propidium iodide (PI) staining assay. MCF-7/ADR cells (2x10⁵ cells/well) were seeded in 60 mm plates and cultured in a humidified incubator for 24 h before treatment with the indicated concentrations (0.5 or 1.0 µM) of pristimerin and 1.0 µM ADR for an additional 8 h. Apoptosis was determined by flow cytometry using Annexin V-FITC Apoptosis Detection Kit II (BD Pharmingen, San Diego, CA, USA), as described previously (13), and a BD FACSCanto™ II (BD Biosciences, San Jose, CA, USA).

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. MCF-7/ADR cells were plated at a density of 1x10⁴ cells per well in 24-well flat-bottom plates, treated with 1.0 µM pristimerin and 1.0 µM ADR for 24 h. The TUNEL assay for in situ detection of apoptosis was performed by using the DeadEnd™ Fluorometric TUNEL System assay kit (Promega Corporation, Madison, WI, USA) as previously reported (13).

Caspase activity assay. After treatment of pristimerin with the indicated concentrations (0, 0.5 or 1.0 µM) and 1.0 µM ADR for 24 h, activity of caspase-8 and -9 was measured using a Caspase Colorimetric Assay kit (Nanjing KeyGen Biotech. Co. Ltd.) according to the manufacturer’s protocol as described previously (13).

Western blotting analysis. Following treatment with pristimerin and/or 1.0 µM ADR at various concentrations (0.5 and 1.0 µM) for 48 h, cells in each dish, including dead cells floating in medium, were harvested and lysed in 1X sampling buffer (Nanjing KeyGen Biotech. Co. Ltd.). Protein concentrations of the lysates were determined using the Pierce Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific, Inc.). An aliquot of the denatured supernatant containing 30 µg of protein was subjected to 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis, and subsequently transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). After blocking with blocking buffer (Tris-buffed saline containing 5% non-fat milk) for 1 h at room temperature, the membranes were incubated overnight at 4˚C with the following specific primary antibodies: Monoclonal mouse anti-human caspase-8 (catalog no. 9746), polyclonal rabbit anti-human caspase-9 (catalog no. 9502), polyclonal rabbit anti-human PARP (catalog no. 9542), polyclonal rabbit anti-human p-Akt (Ser473; catalog no. 9271), monoclonal rabbit anti-human Akt (catalog no. 9272), monoclonal rabbit anti-human p-Bad (Ser136; catalog no. 9265), monoclonal rabbit anti-human Bad (catalog no. 9292), polyclonal rabbit anti-human Bcl-xL (catalog no. 2672) and monoclonal mouse anti-human GAPDH (catalog no. 60004-1; dilution, 1:10,000; Proteintech Group, Inc., Chicago, IL, USA). All the antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA) and were diluted at 1:1,000, unless otherwise specified. Further incubation with

---

**Table I.** IC₅₀ values of pristimerin on MCF-7/ADR cells.

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>IC₅₀</th>
<th>RF</th>
<th>IC₅₀</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7</td>
<td>1.12</td>
<td>-</td>
<td>0.59</td>
<td>-</td>
</tr>
<tr>
<td>MCF-7/ADR</td>
<td>16.29</td>
<td>14.54</td>
<td>0.43</td>
<td>0.73</td>
</tr>
</tbody>
</table>

IC₅₀, the concentration of drug that inhibited cell survival by 50%; ADR, adriamycin; RF, resistance factor.

---

**Figure 1.** Effect of pristimerin on the growth of MCF-7/ADR cells. Cells were seeded in 96-well plates and incubated with the indicated concentrations of pristimerin for 48 h at 37˚C. Cell viabilities were determined by MTS assay. Data points are presented as mean ± standard deviation of triplicate experiments. ADR, adriamycin.
appropriate horseradish peroxidase-conjugated goat anti-rabbit (catalog. no. SA00001-2; 1:4,000) or goat anti-mouse (catalog no. SA00001-1: 1:4,000) IgG secondary antibodies (Protein-Tech Group, Inc.), depending on the primary antibody used, was performed for 1 h at room temperature. Detection of staining signals was performed using the Pierce Enhanced Chemiluminescence Western Blotting Substrate (Thermo Fisher Scientific, Inc.).

**Statistical analysis.** The data given in the text are expressed as the mean ± standard deviation (SD). Comparisons between groups for statistical significance were carried out with a two-tailed Student’s t-test using SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). In all cases, P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Growth inhibition of ADR-resistant MCF-7 cell by pristimerin.** The effect of pristimerin on the growth of the ADR-resistant human breast cancer cell line MCF-7/ADR and the parental sensitive MCF-7 cells was investigated using the MTS assay. After treatment with pristimerin for 48 h, MCF-7/ADR cells displayed markedly inhibited growth, compared with control cells treated with vehicle, in a dose-dependent manner (Fig. 1). The calculated IC$_{50}$ values, i.e. the concentrations of pristimerin that inhibited cell survival by 50%, were 0.43 µM for MCF-7/ADR and 0.59 µM for MCF-7, respectively. Pristimerin reduced the RF from 14.54 to 0.73 (Table I), which revealed that pristimerin reversed the ADR resistance of MCF-7/ADR cells.

**Pristimerin induced apoptosis in MCF-7/ADR cells.** To investigate whether pristimerin was able to induce apoptosis in MCF-7/ADR cells, an Annexin V-FITC/PI binding assay was performed. As shown in Fig. 2, after 8 h treatment with pristimerin at 0.5, 1.0 µM, the percentage of apoptotic MCF-7/ADR cells (Annexin V$^+$/PI$^-$), markedly increased in a dose-dependent manner. In addition, when the TUNEL assay was used to evaluate apoptosis-induced nuclear DNA fragmentation as a late event during the apoptotic process, a higher amount of TUNEL-positive cells was demonstrated in MCF-7/ADR cells treated for 24 h with pristimerin at 1.0 µM compared to the control (Fig. 3). These results strongly indicated a proapoptotic effect of pristimerin on MCF-7/ADR cells.
Activation of both the intrinsic and extrinsic apoptotic pathways by pristimerin in MCF-7/ADR cells. Caspase activation serves a central role in the execution of apoptosis (15). To further understand the apoptotic process in MCF-7/ADR cells, caspase-9 and -8, the proapoptotic caspases in intrinsic and extrinsic apoptotic pathways, respectively, were examined using western blotting and enzymatic activity assays. As shown in Fig. 4A, pristimerin treatment dose-dependently activated the cleavage of inactive procaspase-9 and -8 in MCF-7/ADR cells. Consistent with the results of western blotting analysis, the enzymatic activity of caspase-8 and -9 markedly increased in a dose-dependent manner after treatment with pristimerin at 0.5, 1.0 µM (Fig. 4B). The effector molecule PARP was cleaved into the 85 kDa fragment after pristimerin treatment in MCF-7/ADR cells (Fig. 4A). These results indicated that apoptosis induced by pristimerin in MCF-7/ADR cells may involve both intrinsic and extrinsic pathways.

Suppression of Akt activation and its downstream substrates by pristimerin. In an effort to further understand the signaling cascade that mediates the proapoptotic effect of pristimerin on MCF-7/ADR cells, whether pristimerin modulates the activation of Akt was next investigated. As shown in Fig. 5, Akt was found to be constitutively activated upon treatment with ADR in MCF-7/ADR cells (Fig. 5A), and pristimerin treatment suppressed constitutively phosphorylated Akt levels in a dose-dependent manner without an effect on total Akt expression (Fig. 5B). Phospho-Bad (Ser136) was a proapoptotic member of the Bcl-2 family. Dephosphorylated Bad forms a heterodimer with Bcl-2 and Bcl-xL. When Bad is phosphorylated by Akt, it promotes binding of Bad to 14-3-3 proteins (16). This leaves Bcl-2 free to inhibit apoptosis and then promote cell survival. Consistent with the suppression of Akt activation, pristimerin treatment reduced phosphorylation of Bad (Ser136) dose-dependently without an effect on total Bad expression (Fig. 5B).
of cellular processes including cell death and survival, cell proliferation, protein synthesis and cell metabolism (23,24). Accumulating evidence has indicated that activation of the PI3K/Akt pathway may confer acquired resistance to chemotherapeutic drugs with different mechanisms of actions: ADR, mitoxantrone, 5-fluorouracil, etoposide, camptothecin, etc (20,21). In breast cancer cells, activation of Akt by HER2/PI3K is involved in conferring broad-spectrum chemoresistance. Therefore, Akt is considered to be a novel target to develop therapeutic strategy to improve the outcome of breast cancer chemotherapy (25). In agreement with previous reports, the present study revealed that Akt was indeed constitutively activated upon ADR treatment in MCF-7/ADR cells. The ability of pristimerin to suppress the Akt signaling pathways has been previously reported in a number of sensitive cancer cell lines (6,26). For ADR-resistant MCF-7/ADR cells, it was demonstrated that pristimerin treatment also resulted in a dose-dependent reduction in phospho-Ser473-Akt without an effect on total Akt expression. Bad and Bcl-xL are two crucial mediators downstream of Akt signaling, and dysregulation of Bad and Bcl-xL has been linked to chemoresistance (27-30). In the present study, in parallel with the observed reduction of Akt phosphorylation, phosphorylation of Bad was inhibited and Bcl-xL was downregulated in response to pristimerin treatment in MCF-7/ADR cells.

In conclusion, the results of the present study indicate that pristimerin is a potent apoptosis inducer in breast cancer cells resistant to ADR treatments, and its mechanism is relevant with the suppression of Akt signaling, which indicates the therapeutic value of pristimerin as a potential MDR reversing agent for breast cancer chemotherapy.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81101682).

References


